Effects of adipocyte-conditioned cell culture media on S1P treatment of human triple-negative breast cancer cells.
Journal
PloS one
ISSN: 1932-6203
Titre abrégé: PLoS One
Pays: United States
ID NLM: 101285081
Informations de publication
Date de publication:
2023
2023
Historique:
received:
03
01
2023
accepted:
09
05
2023
medline:
25
5
2023
pubmed:
23
5
2023
entrez:
23
5
2023
Statut:
epublish
Résumé
Sphingosine-1-phosphate (S1P) is a potent sphingolipid metabolite that regulates a wide range of biological functions such as cell proliferation, cell apoptosis and angiogenesis. Its cellular level is elevated in breast cancer, which, in turn, would promote cancer cell proliferation, survival, growth and metastasis. However, the cellular concentration of S1P is normally in the low nanomolar range, and our previous studies showed that S1P selectively induced apoptosis of breast cancer cells at high concentrations (high nanomolar to low micromolar). Thus, local administration of high-concentration S1P alone or in combination of chemotherapy agents could be used to treat breast cancer. The breast mainly consists of mammary gland and connective tissue stroma (adipose), which are dynamically interacting each other. Thus, in the current study, we evaluated how normal adipocyte-conditioned cell culture media (AD-CM) and cancer-associated adipocyte-conditioned cell culture media (CAA-CM) would affect high-concentration S1P treatment of triple-negative breast cancer (TNBC) cells. Both AD-CM and CAA-CM may suppress the anti-proliferative effect and reduce nuclear alteration/apoptosis caused by high-concentration S1P. This implicates that adipose tissue is likely to be detrimental to local high-concentration S1P treatment of TNBC. Because the interstitial concentration of S1P is about 10 times higher than its cellular level, we undertook a secretome analysis to understand how S1P would affect the secreted protein profile of differentiated SGBS adipocytes. At 100 nM S1P treatment, we identified 36 upregulated and 21 downregulated secretome genes. Most of these genes are involved in multiple biological processes. Further studies are warranted to identify the most important secretome targets of S1P in adipocytes and illustrate the mechanism on how these target proteins affect S1P treatment of TNBC.
Identifiants
pubmed: 37220155
doi: 10.1371/journal.pone.0286111
pii: PONE-D-23-00212
pmc: PMC10204952
doi:
Substances chimiques
sphingosine 1-phosphate
26993-30-6
Lysophospholipids
0
Culture Media, Conditioned
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
e0286111Informations de copyright
Copyright: © 2023 Wu et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Déclaration de conflit d'intérêts
The authors have declared that no competing interests exist.
Références
Proc Natl Acad Sci U S A. 2017 Mar 21;114(12):3121-3126
pubmed: 28270600
Pharmacol Rev. 2008 Jun;60(2):181-95
pubmed: 18552276
Cancers (Basel). 2021 Aug 03;13(15):
pubmed: 34359819
Nature. 2017 Jun 1;546(7656):158-161
pubmed: 28538737
Cancer Res. 2018 Apr 1;78(7):1713-1725
pubmed: 29351902
Nat Commun. 2014 Sep 25;5:4806
pubmed: 25254944
Front Oncol. 2020 Mar 20;10:289
pubmed: 32266132
Front Oncol. 2021 Aug 13;11:705911
pubmed: 34485137
Eur J Pharmacol. 2018 Aug 15;833:173-182
pubmed: 29886240
Onco Targets Ther. 2021 Mar 05;14:1727-1735
pubmed: 33707955
Int J Mol Med. 2017 Feb;39(2):243-252
pubmed: 28075451
Nat Rev Cancer. 2009 Dec;9(12):874-85
pubmed: 19935676
Mol Cancer Ther. 2012 Jan;11(1):24-33
pubmed: 22027689
Cells. 2020 Jul 13;9(7):
pubmed: 32668665
Breast Cancer Res. 2019 Jan 17;21(1):7
pubmed: 30654824
Breast Cancer Res Treat. 2018 Nov;172(1):33-43
pubmed: 30043096
J Transl Med. 2011 Sep 22;9:157
pubmed: 21936950
Front Oncol. 2022 Jun 22;12:820968
pubmed: 35814391
Sci Signal. 2019 Nov 26;12(609):
pubmed: 31772123
Science. 2007 Apr 13;316(5822):295-8
pubmed: 17363629
Cell Signal. 2021 Jun;82:109959
pubmed: 33631318
Cell Mol Biol Lett. 2019 Jun 06;24:38
pubmed: 31182966
Med Res Rev. 2017 Jan;37(1):3-51
pubmed: 27480072
Cell Signal. 2007 Jun;19(6):1328-38
pubmed: 17307336
Crit Rev Food Sci Nutr. 2020;60(22):3770-3792
pubmed: 31899947
Nat Rev Immunol. 2008 Oct;8(10):753-63
pubmed: 18787560
J Biol Chem. 2003 Oct 10;278(41):40330-6
pubmed: 12835323
Nature. 2021 Apr;592(7853):290-295
pubmed: 33658712
J Endocrinol. 2014 Jan 27;220(3):R25-35
pubmed: 24323911
Int J Mol Sci. 2021 Apr 21;22(9):
pubmed: 33919234
Int J Mol Sci. 2020 Dec 05;21(23):
pubmed: 33291440
Mol Diagn Ther. 2019 Aug;23(4):467-487
pubmed: 31115798
Invest New Drugs. 2011 Apr;29(2):396-9
pubmed: 20041340
Science. 2009 Sep 4;325(5945):1254-7
pubmed: 19729656
FASEB J. 2019 Jun;33(6):7180-7191
pubmed: 30844311
J Mammary Gland Biol Neoplasia. 2016 Jun;21(1-2):9-17
pubmed: 27194029
Cell Signal. 2017 Apr;32:85-92
pubmed: 28108260
Cancer Res. 2012 Mar 15;72(6):1416-27
pubmed: 22282662
Nat Rev Cancer. 2010 Jul;10(7):489-503
pubmed: 20555359
J Hepatol. 2013 Jul;59(1):114-23
pubmed: 23466305
Invest New Drugs. 2020 Oct;38(5):1316-1325
pubmed: 32060788
Front Mol Biosci. 2021 May 14;8:683767
pubmed: 34055895
Nat Rev Cancer. 2018 Jan;18(1):33-50
pubmed: 29147025
Int J Mol Sci. 2018 Jan 31;19(2):
pubmed: 29385066
Clin Cancer Res. 2015 Apr 15;21(8):1925-1934
pubmed: 25589614
Med Sci Monit. 2007 Nov;13(11):BR231-239
pubmed: 17968289
Cancer Res. 1999 Sep 15;59(18):4732-7
pubmed: 10493533
J Mammary Gland Biol Neoplasia. 2010 Sep;15(3):279-90
pubmed: 20717712
Science. 2018 Jan 5;359(6371):114-119
pubmed: 29302015
J Cancer. 2013;4(4):315-9
pubmed: 23569464